1133 related articles for article (PubMed ID: 22521072)
1. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Garber AJ; King AB; Del Prato S; Sreenan S; Balci MK; Muñoz-Torres M; Rosenstock J; Endahl LA; Francisco AM; Hollander P;
Lancet; 2012 Apr; 379(9825):1498-507. PubMed ID: 22521072
[TBL] [Abstract][Full Text] [Related]
2. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Heller S; Buse J; Fisher M; Garg S; Marre M; Merker L; Renard E; Russell-Jones D; Philotheou A; Francisco AM; Pei H; Bode B;
Lancet; 2012 Apr; 379(9825):1489-97. PubMed ID: 22521071
[TBL] [Abstract][Full Text] [Related]
3. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.
Zinman B; Fulcher G; Rao PV; Thomas N; Endahl LA; Johansen T; Lindh R; Lewin A; Rosenstock J; Pinget M; Mathieu C
Lancet; 2011 Mar; 377(9769):924-31. PubMed ID: 21396703
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.
Zinman B; DeVries JH; Bode B; Russell-Jones D; Leiter LA; Moses A; Johansen T; Ratner R;
Lancet Diabetes Endocrinol; 2013 Oct; 1(2):123-31. PubMed ID: 24622318
[TBL] [Abstract][Full Text] [Related]
5. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
Philis-Tsimikas A; Klonoff DC; Khunti K; Bajaj HS; Leiter LA; Hansen MV; Troelsen LN; Ladelund S; Heller S; Pieber TR;
Diabetologia; 2020 Apr; 63(4):698-710. PubMed ID: 31984443
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.
Davies MJ; Gross JL; Ono Y; Sasaki T; Bantwal G; Gall MA; Niemeyer M; Seino H;
Diabetes Obes Metab; 2014 Oct; 16(10):922-30. PubMed ID: 24702700
[TBL] [Abstract][Full Text] [Related]
7. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.
Bode BW; Buse JB; Fisher M; Garg SK; Marre M; Merker L; Renard E; Russell-Jones DL; Hansen CT; Rana A; Heller SR;
Diabet Med; 2013 Nov; 30(11):1293-7. PubMed ID: 23710902
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study.
Frias J; Chien J; Zhang Q; Chigutsa E; Landschulz W; Syring K; Wullenweber P; Haupt A; Kazda C
Lancet Diabetes Endocrinol; 2023 Mar; 11(3):158-168. PubMed ID: 36758572
[TBL] [Abstract][Full Text] [Related]
9. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
10. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.
Mathieu C; Ásbjörnsdóttir B; Bajaj HS; Lane W; Matos ALSA; Murthy S; Stachlewska K; Rosenstock J
Lancet; 2023 Jun; 401(10392):1929-1940. PubMed ID: 37156252
[TBL] [Abstract][Full Text] [Related]
11. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial.
Rodbard HW; Cariou B; Zinman B; Handelsman Y; Philis-Tsimikas A; Skjøth TV; Rana A; Mathieu C;
Diabet Med; 2013 Nov; 30(11):1298-304. PubMed ID: 23952326
[TBL] [Abstract][Full Text] [Related]
12. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
Franek E; Haluzík M; Canecki Varžić S; Sargin M; Macura S; Zacho J; Christiansen JS
Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST
Hirsch IB; Franek E; Mersebach H; Bardtrum L; Hermansen K
Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
[TBL] [Abstract][Full Text] [Related]
14. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
[TBL] [Abstract][Full Text] [Related]
15. Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial.
Rodbard HW; Cariou B; Pieber TR; Endahl LA; Zacho J; Cooper JG
Diabetes Obes Metab; 2016 Mar; 18(3):274-80. PubMed ID: 26592732
[TBL] [Abstract][Full Text] [Related]
16. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
Wysham C; Bhargava A; Chaykin L; de la Rosa R; Handelsman Y; Troelsen LN; Kvist K; Norwood P
JAMA; 2017 Jul; 318(1):45-56. PubMed ID: 28672317
[TBL] [Abstract][Full Text] [Related]
17. Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled, non-inferiority trial.
Mathiesen ER; Alibegovic AC; Corcoy R; Dunne F; Feig DS; Hod M; Jia T; Kalyanam B; Kar S; Kautzky-Willer A; Marchesini C; Rea RD; Damm P;
Lancet Diabetes Endocrinol; 2023 Feb; 11(2):86-95. PubMed ID: 36623517
[TBL] [Abstract][Full Text] [Related]
18. Insulin degludec improves health-related quality of life (SF-36® ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials.
Freemantle N; Meneghini L; Christensen T; Wolden ML; Jendle J; Ratner R
Diabet Med; 2013 Feb; 30(2):226-32. PubMed ID: 23199058
[TBL] [Abstract][Full Text] [Related]
19. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).
Zinman B; Philis-Tsimikas A; Cariou B; Handelsman Y; Rodbard HW; Johansen T; Endahl L; Mathieu C;
Diabetes Care; 2012 Dec; 35(12):2464-71. PubMed ID: 23043166
[TBL] [Abstract][Full Text] [Related]
20. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]